IPSEN (OTCMKTS:IPSEY) Sees Significant Drop in Short Interest

IPSEN (OTCMKTS:IPSEY) was the recipient of a large drop in short interest during the month of September. As of September 15th, there was short interest totaling 41 shares, a drop of 96.6% from the August 31st total of 1,214 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 2,201 shares, the days-to-cover ratio is currently 0.0 days.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Zacks Research raised IPSEN to a “hold” rating in a research report on Friday, May 29th. HC Wainwright restated a “buy” rating on shares of IPSEN in a research note on Tuesday, June 30th. Jefferies Financial Group downgraded shares of IPSEN from a “hold” rating to a “moderate sell” rating in a research note on Sunday, August 2nd. Finally, Barclays raised shares of IPSEN from a “strong sell” rating to a “hold” rating in a research report on Thursday, September 17th. Two analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold”.

IPSEN Stock Performance

Shares of OTCMKTS:IPSEY remained flat at $41.97 during trading on Thursday. The stock had a trading volume of 106 shares, compared to its average volume of 611. IPSEN has a one year low of $32.02 and a one year high of $51.10. The company has a fifty day moving average price of $46.15 and a two-hundred day moving average price of $46.59.

About IPSEN

Ipsen SA is a France-based biopharmaceutical company that develops and commercializes specialty medicines for serious diseases. Its primary focus areas are oncology, rare diseases and neuroscience, with research and development activities aimed at addressing conditions that often have limited treatment options.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected neurological and muscular conditions, and oncology treatments including Cabometyx and Onivyde.